Imaging-proven Venous Thromboembolism Breast Cancer in a Tertiary Hospital in the Philippines

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Imaging
Cancer Care Delivery in Low Resource Environments
Breast Cancer
Supportive and Palliative Care
Presenter Amabelle Trina Gerona
Citation Annals of Oncology (2018) 29 (suppl_9): ix8-ix12. 10.1093/annonc/mdy427
Authors A.T.B. Gerona
  • Medical Oncology, ST. Luke's Medical Center, 11104 - Quezon City/PH



Venous thromboembolism (VTE) is a common cause of mortality in cancer patients. This study looks into the most common malignancy in our institution, breast cancer, and its association with VTE.


Anonymised hospital patient database for years 2010-2015 with either Venous Dupplex Scan or Computed Tomographic Pulmonary Angiography. Each result was reviewed bearing acute pulmonary embolism or acute venous thrombosis. Only the first VTE event after the diagnosis of cancer was considered followed by chart review.


A total of 10,380 CTPA/Venous duplex scans were performed, with 916 (8.8%) positive VTE. Malignancy was seen in 208 (2%) with the majority 17.9% (n = 37) having breast cancer. Mean age for breast cancer with VTE was 60, majority 24 (64.8%) having normal BMI. Most had lower extremity VTE 28 (75.67%) presented as swelling of extremities 18 (48.6%). VTE within one year of cancer diagnosis was noted in 57.7% while 43.2% were alive for >2 years from VTE diagnosis. Active cancer management during diagnosis were chemotherapy 45.9%, hormonal therapy 32.4%, surgery 10.8%, while 10.8% had VTE as the presenting symptom of cancer diagnosis. VTE during chemotherapy days was seen in 64.7% while 35% had VTE one month after completion of chemotherapy. Those with hormonal therapy 10 (83.3%) had aromatase inhibitor, while only 2 (5.4%) received tamoxifen.


Breast cancer with VTE in our institution have normal BMI, presenting mostly as swelling of lower extremity. VTE was seen mostly within one year of cancer diagnosis and patients were alive for more than two years from VTE diagnosis. Active cancer management during VTE diagnosis was mostly during chemotherapy, followed by hormonal treatment with aromatase inhibitor.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Dr. Agnes E. Gorospe.


Has not received any funding.


The author has declared no conflicts of interest.